Failure of the gut barrier system enhances liver injury in rats

Protection of hepatocytes by gut-derived hepatocyte growth factor

Yasuhiro Choda, Yoshinori Morimoto, Hideaki Miyaso, Susumu Shinoura, Shinya Saito, Takahito Yagi, Hiromi Iwagaki, Noriaki Tanaka

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Clinical and experimental studies suggest that impairment of the mucosal barrier system increases gut-derived endotoxin in the portal blood, which causes liver injury. The aim of this study was to elucidate the mechanism of liver injury caused by gut defence failure. Design: Wistar rats were administered either enteral lipopolysaccharide (LPS) or LPS via the portal vein. Methods: Blood samples were collected via the inferior vena cava at necropsy. Serum aspartate transaminase (AST) and alanine transaminase (ALT) were analysed by standard enzymatic procedures and cytokines [tumour necrosis factor-α, interleukin (IL)-1β, interferon-γ, IL-6 and hepatocyte growth factor (HGF)] were measured by enzyme-linked immunosorbent assay. Livers were removed and snap-frozen in liquid nitrogen. CD14, CD68, Toll-like receptor (TLR) 2, TLR4 and Fas ligand (FasL) were analysed immunohistochemically. Expression of TLR2, TLR4 and CD14 mRNA was determined by reverse transcriptase-polymerase chain reaction. Results: In enterally-treated rats, AST and ALT were not increased and cytokine levels were under the limits of detection in the absence of a rise in HGF. Enteral administration of LPS increased HGF dose-dependently. Injection of LPS in the portal vein resulted in significant increases in AST, ALT, tumour necrosis factor-α, IL-1β, interferon-γ and IL-6 levels, but no change in HGF levels. Immunohistochemical analysis revealed that intraportal LPS administration increased CD14, TLR4, CD68 and FasL. Reverse transcriptase-polymerase chain reaction analysis demonstrated that TLR4 mRNA expression was upregulated 0.5 h after intraportal LPS administration. Conclusions: Our data suggest that Kupffer cell activation mediated by intraportal LPS via TLR4 is involved in liver injury, possibly through both tumour necrosis factor-α/IL-1β and FasL, and that lack of HGF activity in the impaired gut could not counteract liver injury.

Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalEuropean Journal of Gastroenterology and Hepatology
Volume16
Issue number10
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Hepatocyte Growth Factor
Lipopolysaccharides
Hepatocytes
Liver
Wounds and Injuries
Fas Ligand Protein
Aspartate Aminotransferases
Alanine Transaminase
Interleukin-1
Tumor Necrosis Factor-alpha
Portal Vein
Reverse Transcriptase Polymerase Chain Reaction
Interferons
Small Intestine
Interleukin-6
Cytokines
Toll-Like Receptor 2
Messenger RNA
Kupffer Cells
Inferior Vena Cava

Keywords

  • Apoptosis
  • Fas ligand
  • Gut defence
  • Lipopolysaccharide
  • Toll-like receptor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Failure of the gut barrier system enhances liver injury in rats : Protection of hepatocytes by gut-derived hepatocyte growth factor. / Choda, Yasuhiro; Morimoto, Yoshinori; Miyaso, Hideaki; Shinoura, Susumu; Saito, Shinya; Yagi, Takahito; Iwagaki, Hiromi; Tanaka, Noriaki.

In: European Journal of Gastroenterology and Hepatology, Vol. 16, No. 10, 10.2004, p. 1017-1025.

Research output: Contribution to journalArticle

Choda, Yasuhiro ; Morimoto, Yoshinori ; Miyaso, Hideaki ; Shinoura, Susumu ; Saito, Shinya ; Yagi, Takahito ; Iwagaki, Hiromi ; Tanaka, Noriaki. / Failure of the gut barrier system enhances liver injury in rats : Protection of hepatocytes by gut-derived hepatocyte growth factor. In: European Journal of Gastroenterology and Hepatology. 2004 ; Vol. 16, No. 10. pp. 1017-1025.
@article{d5e1e66d2bd14467bf885f962b812487,
title = "Failure of the gut barrier system enhances liver injury in rats: Protection of hepatocytes by gut-derived hepatocyte growth factor",
abstract = "Objective: Clinical and experimental studies suggest that impairment of the mucosal barrier system increases gut-derived endotoxin in the portal blood, which causes liver injury. The aim of this study was to elucidate the mechanism of liver injury caused by gut defence failure. Design: Wistar rats were administered either enteral lipopolysaccharide (LPS) or LPS via the portal vein. Methods: Blood samples were collected via the inferior vena cava at necropsy. Serum aspartate transaminase (AST) and alanine transaminase (ALT) were analysed by standard enzymatic procedures and cytokines [tumour necrosis factor-α, interleukin (IL)-1β, interferon-γ, IL-6 and hepatocyte growth factor (HGF)] were measured by enzyme-linked immunosorbent assay. Livers were removed and snap-frozen in liquid nitrogen. CD14, CD68, Toll-like receptor (TLR) 2, TLR4 and Fas ligand (FasL) were analysed immunohistochemically. Expression of TLR2, TLR4 and CD14 mRNA was determined by reverse transcriptase-polymerase chain reaction. Results: In enterally-treated rats, AST and ALT were not increased and cytokine levels were under the limits of detection in the absence of a rise in HGF. Enteral administration of LPS increased HGF dose-dependently. Injection of LPS in the portal vein resulted in significant increases in AST, ALT, tumour necrosis factor-α, IL-1β, interferon-γ and IL-6 levels, but no change in HGF levels. Immunohistochemical analysis revealed that intraportal LPS administration increased CD14, TLR4, CD68 and FasL. Reverse transcriptase-polymerase chain reaction analysis demonstrated that TLR4 mRNA expression was upregulated 0.5 h after intraportal LPS administration. Conclusions: Our data suggest that Kupffer cell activation mediated by intraportal LPS via TLR4 is involved in liver injury, possibly through both tumour necrosis factor-α/IL-1β and FasL, and that lack of HGF activity in the impaired gut could not counteract liver injury.",
keywords = "Apoptosis, Fas ligand, Gut defence, Lipopolysaccharide, Toll-like receptor",
author = "Yasuhiro Choda and Yoshinori Morimoto and Hideaki Miyaso and Susumu Shinoura and Shinya Saito and Takahito Yagi and Hiromi Iwagaki and Noriaki Tanaka",
year = "2004",
month = "10",
doi = "10.1097/00042737-200410000-00011",
language = "English",
volume = "16",
pages = "1017--1025",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Failure of the gut barrier system enhances liver injury in rats

T2 - Protection of hepatocytes by gut-derived hepatocyte growth factor

AU - Choda, Yasuhiro

AU - Morimoto, Yoshinori

AU - Miyaso, Hideaki

AU - Shinoura, Susumu

AU - Saito, Shinya

AU - Yagi, Takahito

AU - Iwagaki, Hiromi

AU - Tanaka, Noriaki

PY - 2004/10

Y1 - 2004/10

N2 - Objective: Clinical and experimental studies suggest that impairment of the mucosal barrier system increases gut-derived endotoxin in the portal blood, which causes liver injury. The aim of this study was to elucidate the mechanism of liver injury caused by gut defence failure. Design: Wistar rats were administered either enteral lipopolysaccharide (LPS) or LPS via the portal vein. Methods: Blood samples were collected via the inferior vena cava at necropsy. Serum aspartate transaminase (AST) and alanine transaminase (ALT) were analysed by standard enzymatic procedures and cytokines [tumour necrosis factor-α, interleukin (IL)-1β, interferon-γ, IL-6 and hepatocyte growth factor (HGF)] were measured by enzyme-linked immunosorbent assay. Livers were removed and snap-frozen in liquid nitrogen. CD14, CD68, Toll-like receptor (TLR) 2, TLR4 and Fas ligand (FasL) were analysed immunohistochemically. Expression of TLR2, TLR4 and CD14 mRNA was determined by reverse transcriptase-polymerase chain reaction. Results: In enterally-treated rats, AST and ALT were not increased and cytokine levels were under the limits of detection in the absence of a rise in HGF. Enteral administration of LPS increased HGF dose-dependently. Injection of LPS in the portal vein resulted in significant increases in AST, ALT, tumour necrosis factor-α, IL-1β, interferon-γ and IL-6 levels, but no change in HGF levels. Immunohistochemical analysis revealed that intraportal LPS administration increased CD14, TLR4, CD68 and FasL. Reverse transcriptase-polymerase chain reaction analysis demonstrated that TLR4 mRNA expression was upregulated 0.5 h after intraportal LPS administration. Conclusions: Our data suggest that Kupffer cell activation mediated by intraportal LPS via TLR4 is involved in liver injury, possibly through both tumour necrosis factor-α/IL-1β and FasL, and that lack of HGF activity in the impaired gut could not counteract liver injury.

AB - Objective: Clinical and experimental studies suggest that impairment of the mucosal barrier system increases gut-derived endotoxin in the portal blood, which causes liver injury. The aim of this study was to elucidate the mechanism of liver injury caused by gut defence failure. Design: Wistar rats were administered either enteral lipopolysaccharide (LPS) or LPS via the portal vein. Methods: Blood samples were collected via the inferior vena cava at necropsy. Serum aspartate transaminase (AST) and alanine transaminase (ALT) were analysed by standard enzymatic procedures and cytokines [tumour necrosis factor-α, interleukin (IL)-1β, interferon-γ, IL-6 and hepatocyte growth factor (HGF)] were measured by enzyme-linked immunosorbent assay. Livers were removed and snap-frozen in liquid nitrogen. CD14, CD68, Toll-like receptor (TLR) 2, TLR4 and Fas ligand (FasL) were analysed immunohistochemically. Expression of TLR2, TLR4 and CD14 mRNA was determined by reverse transcriptase-polymerase chain reaction. Results: In enterally-treated rats, AST and ALT were not increased and cytokine levels were under the limits of detection in the absence of a rise in HGF. Enteral administration of LPS increased HGF dose-dependently. Injection of LPS in the portal vein resulted in significant increases in AST, ALT, tumour necrosis factor-α, IL-1β, interferon-γ and IL-6 levels, but no change in HGF levels. Immunohistochemical analysis revealed that intraportal LPS administration increased CD14, TLR4, CD68 and FasL. Reverse transcriptase-polymerase chain reaction analysis demonstrated that TLR4 mRNA expression was upregulated 0.5 h after intraportal LPS administration. Conclusions: Our data suggest that Kupffer cell activation mediated by intraportal LPS via TLR4 is involved in liver injury, possibly through both tumour necrosis factor-α/IL-1β and FasL, and that lack of HGF activity in the impaired gut could not counteract liver injury.

KW - Apoptosis

KW - Fas ligand

KW - Gut defence

KW - Lipopolysaccharide

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=6944246195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6944246195&partnerID=8YFLogxK

U2 - 10.1097/00042737-200410000-00011

DO - 10.1097/00042737-200410000-00011

M3 - Article

VL - 16

SP - 1017

EP - 1025

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 10

ER -